MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bjh.15018

Медицинская библиотека · British journal of haematology · 2017

The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.

Jain Preetesh, Nogueras González Graciela M, Kanagal-Shamanna Rashmi, Rozovski Uri, Sarwari Nawid, Tam Constantine, Wierda William G, Thompson Philip A, Jain Nitin, Luthra Rajyalakshmi, Quesada Andres, Sanchez-Petitto Gabriela, Ferrajoli Alessandra, Burger Jan, Kantarjian Hagop, Cortes Jorge, O'Brien Susan, Keating Michael J, Estrov Zeev

СтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

The degree of somatic hypermutation, determined as percent deviation of immunoglobulin heavy chain gene variable region sequence from the germline (IGHV%), is an important prognostic factor in chronic lymphocytic leukaemia (CLL). Currently, a cut-off of 2% deviation or 98% sequence identity to germline in IGHV sequence is routinely used to dichotomize CLL patients into mutated and unmutated groups. Because dissimilar IGHV% cut-offs of 1-5% were identified in different studies, we wondered whether no cut-off should be applied and IGHV% treated as a continuous variable. We analysed the significance of IGHV% in 203 CLL patients enrolled on the original frontline fludarabine, cyclophosphamide and rituximab (FCR) trial with a median of 10 years follow-up. Using the Cox Proportional Hazard model, IGHV% was identified as a continuous variable that is significantly associated with progression-free (PFS) and overall survival (OS) (P < 0·001). Furthermore, we validated this finding in 323 patients treated with FCR off-protocol and in the total cohort (n = 535). Multivariate analysis revealed a continuous trend. Higher IGHV% levels were incrementally associated with favorable PFS and OS in both FCR-treated cohorts (P < 0·001, both cohorts). Taken together, our data suggest that IGHV% is a continuous variable in CLL patients treated with FCR.

Для цитирования: Jain Preetesh, Nogueras González Graciela M, Kanagal-Shamanna Rashmi, Rozovski Uri, Sarwari Nawid, Tam Constantine, Wierda William G, Thompson Philip A, Jain Nitin, Luthra Rajyalakshmi, Quesada Andres, Sanchez-Petitto Gabriela, Ferrajoli Alessandra, Burger Jan, Kantarjian Hagop, Cortes Jorge, O'Brien Susan, Keating Michael J, Estrov Zeev. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.. British journal of haematology. 2017. DOI: 10.1111/bjh.15018.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.